{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-10","spread":"-10","upperLimit":"-10","value":"-10.0"},{"groupId":"OG001","lowerLimit":"-17","spread":"-17","upperLimit":"45","value":"6.3"},{"groupId":"OG002","lowerLimit":"6","spread":"6","upperLimit":"6","value":"6.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"12-lead ECG were recorded after the participants have rested for at least 15 minutes in supine position. Change from baseline in 12-Lead ECG findings that is QT interval - Fridericia's correction formula at pre-dose on Cycle 2 Day 1 were reported.","dispersionType":"Full Range","groups":[{"description":"Participants received M3258 at a dose of 10 milligrams (mg) orally, once daily (QD) until disease progression.","id":"OG000","title":"M3258 10 mg QD"},{"description":"Participants received M3258 at a dose of 10 mg orally, twice per week on Day 1 and Day 4 until disease progression.","id":"OG001","title":"M3258 10 mg Twice Per Week"},{"description":"Participants received M3258 at a dose of 20 mg orally, twice per week on Day 1 and Day 4 until disease progression.","id":"OG002","title":"M3258 20 mg Twice Per Week"}],"paramType":"MEAN","populationDescription":"Safety analysis set included all participants who were administered any dose of the study medication. Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 pre-dose (Baseline), pre-dose on Cycle 2 Day 1 (each Cycle is of 28 days)","title":"Part A: Change From Baseline in 12-lead Electrocardiogram (ECG) Findings: QT Interval - Fridericia's Correction Formula","type":"PRIMARY","unitOfMeasure":"milliseconds (msec)"}